Q-omics provides the consensus-scored VPS26BP1 profile across patient tissues and cancer cell-line models. VPS26BP1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, VPS26BP1 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, VPS26BP1 RNA expression shows 7,011 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight ACC, BRCA, and LAML as cancer lineages where VPS26BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS26BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS26BP1 survival associations across molecular data types. VPS26BP1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS26BP1 RNA expression–survival associations across cancer types. High VPS26BP1 expression shows unfavorable associations in ACC, THYM, SKCM, COAD and MESO, but favorable associations in LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for VPS26BP1 RNA expression.
This table summarizes VPS26BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for VPS26BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS26BP1 shows lower tumor expression in BRCA. The BRCA box plot shows higher VPS26BP1 RNA expression in normal versus tumor tissue (log2 FC = −0.106, t-test p = .001).
This table shows molecular features associated with VPS26BP1 in patient tissues and cancer cell lines. In patient samples, VPS26BP1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
